Genetic abnormalities, such as deletions of chromosome 17p and mutations in the TP53 gene, are important prognostic factors in CLL, as they are associated with resistance to therapy and reduced survival (24). This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.